

Supporting Information

Synthesis of 1,2,4,5 tetrasubstituted imidazole via electrochemical C(sp³)-H Amination

Wenxing Wang^a, Shuo Zhang^a, Guang Shi^a, Zhiwei Chen ^{*a}

Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology; College of Pharmaceutical Sciences, Zhejiang University of Technology, Chao Wang Road 18th 310014 Hangzhou, China.

E-mail: chenzhiwei@zjut.edu.cn

Contents


1. General Remarks.....	2
2. Synthetic procedures of starting materials.....	2
3. Synthetic procedure of compound 2 and 3.....	2-3
4. Cyclicvoltammetry.....	3
5. Gram scale reaction.....	3
6. References.....	4
7. Characterization data for the products.....	4-8
8. NMR spectra of products.....	9-34
9. HRMS (ESI) of intermediates.....	35

1. General Remarks


All reagents were obtained from commercial sources (purity > 99%) and used without further purification, unless otherwise indicated. Melting points were determined with a Büchi B-540 capillary melting point apparatus. The ^1H and ^{13}C NMR spectroscopic data were recorded with a Varian instrument at 600 and 150 MHz, respectively, and TMS was used as the internal standard. Mass spectrometry was performed with a Thermo Finnigan LCQ-Advantage instrument. High resolution mass spectral (HRMS) analyze was measured on an Agilent 1290-6540 UHPLC Q-ToF HR-MS System ESI spectrometer. Silica gel for column chromatography was purchased from Qingdao Haiyang Chemical Co., Ltd. Reactions were stirred using Teflon-coated magnetic stir bars

2. Synthetic procedures of starting materials

To a solution of substituted 1,3-dicarbonyl compound (5 mmol) in EtOH (10 mL) at rt were added aniline (15 mmol) (Naphthylamine for **1f**; cyclohexylamine for **1h**; benzylamine for **1i**) and acetic acid (1.4 mL, 25 mmol) in sequence. The reaction was heated at 80 °C until the consumption of the 1,3-dicarbonyl compound as monitored by TLC was complete. After cooling to r.t., the reaction mixture was extracted with CH_2Cl_2 (20 mL \times 3). The combined organic layer was dried over anhydrous Na_2SO_4 , concentrated, and then purified by silica gel column chromatography, giving the enamine **1** in 64–99% yields.



A 50 ml single-mouth flask was charged with methyl acetoacetate (50 mmol, 5.8 g), aniline (60 mmol, 5.6 g), $\text{Zn}(\text{OTf})_2$ (2.5 mmol, 0.9 g), stirred magnetically and monitored by TLC during the reaction (*n*-hexane: ethyl acetate = 10:1). After the reaction, the heating was stopped, cooled to room temperature, and the solution was removed by distillation under reduced pressure using a rotary evaporator to obtain a brown oily liquid, which was extracted with ethyl acetate (3 \times 25 mL), the organic phases were combined, dried with anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. Silica gel column chromatography (*n*-hexane/ethyl acetate/triethylamine = 100:1:1, v/v/v) gave a pale yellow solid. Other enamine nitrogen substitution target products were prepared as described above.




3. Synthetic procedure of compound **3aa**

The electrolysis was carried out in an oven-dried undivided three-necked flask, Enamine ester **1a** (0.5 mmol, 95.5 mg), Benzylamine **2a** (1.5 mmol, 160 mg), KI (0.5 mmol, 83 mg), $^n\text{Bu}_4\text{NBF}_4$ (0.03 M) and DMSO (5 mL) were combined and added. The bottle was equipped with platinum plate (20 mm \times 15 mm) as the anode and platinum plate (20 mm \times 15 mm) as the cathode and was then charged with argon. Then the reaction mixture was stirred at a constant current of 10 mA under room temperature for 10 h. When the reaction was finished, the solution was washed with water (10 mL) and extracted with ethyl acetate (3 \times 10 mL). The combined organic layer was dried with Na_2SO_4 , filtered. The solvent was

removed with a rotary evaporator. The pure product was obtained by flash chromatography on silica gel using petrol ether and ethyl acetate as the eluent (10/1 to 5/1).


4. Cyclic voltammetry

To further understand the formation process of electrochemical oxidation of C-N bonds, cyclic voltammetry (CV) experiments were performed relative to Ag/AgCl, no significant oxidation peaks were observed for **2a** in the range of 0.0-2.0 V (**Background+2a**), while two oxidation peaks were observed for **1a** at 1.61 V and 1.83 V (**Background+1a**). the CV of KI solution showed significant oxidation peaks at 0.81 V and 1.02 V showed distinct oxidation peaks (**Background+KI**). A significant catalytic current can be observed when the feedstock **1a** is added, with an increase in the oxidation peak from 0.001 A to 0.004 A (**Background+KI+1a**), and the increase in the peak current indicates that KI also acts as a medium for the electrochemical reaction.



Cyclic Voltammogram Recorded on (+)C/(-)Pt in *n*-Bu₄NBF₄ (1 mmol)/MeCN (10 mL) at rt; Ag/AgCl as Reference Electrode

5. Gram scale reaction



In an oven-dried undivided three-necked flask (100 mL), enamine ester (5 mmol, 1.37 g), Benzylamine **2a** (15 mmol, 2.78 g), KI (5 mmol, 0.83 g), ⁿBu₄NBF₄ (0.03 M) and DMSO (30 mL) were combined and added. The bottle was equipped with platinum plate (20 mm × 15 mm) as the anode and platinum plate (20 mm × 15 mm) as the cathode and was then charged with argon. Then the reaction mixture was stirred at a constant current of 25 mA under room temperature for 45 h. When the reaction was finished, the solution was washed with water (50 mL) and extracted with ethyl acetate (3×50 mL).

The combined organic layer was dried with Na₂SO₄, filtered. The solvent was removed with a rotary evaporator. The pure product was obtained by flash chromatography on silica gel using petrol ether and ethyl acetate as the eluent (7/1 to 5/1). Yellow solid was obtained in 62% isolated yield.

6. References

- [1] C. A. Brandt, *Synthesis.*, 2004, **10**, 1557-1559.
- [2] L. Wang, J. Zhang, M. Lang, J. Wang, *Org. Chem. Front.*, 2016, **3**, 603-608.
- [3] W. Huang, C. L. Zhu, *Adv. Synth. Catal.*, 2018, **16**, 3117-3123

7. Characterization data for the products

Methyl 5-methyl-1,2-diphenyl-1H-imidazole-4-carboxylate (3aa). Pure white solid (122 mg, 80%) mp: 132-135 °C, eluent (hexane/EtOAc = 7:1), ¹H NMR (400 MHz, CDCl₃) δ 7.47 (td, *J* = 2.6, 1.2 Hz, 3H), 7.36 (d, *J* = 8.2 Hz, 2H), 7.20 (dt, *J* = 13.4, 6.2 Hz, 5H), 3.95 (s, 3H), 2.41 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 146.8, 138.3, 136.4, 129.8, 129.6, 129.3, 128.8, 128.7, 128.6, 128.0, 127.8, 51.5, 10.9. HRMS (ESI): *m/z* calcd for C₁₈H₁₆N₂O₂ [M + H]⁺ 293.1285, found 293.1283.

Methyl 2-(2-chlorophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3ab). Yellow solid (127 mg, 78%) mp: 135-138 °C, eluent (hexane/EtOAc = 7:1), ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.32 (m, 4H), 7.27 (s, 2H), 7.22–7.16 (m, 1H), 7.16 – 7.10 (m, 2H), 3.94 (s, 3H), 2.46 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 144.6, 137.4, 135.0, 134.4, 132.6, 130.7, 129.8, 129.2, 129.1, 129.0, 128.6, 127.4, 126.3, 51.5, 11.0. HRMS (ESI): *m/z* calcd for C₁₈H₁₅ClN₂O₂ [M + H]⁺ 327.0895, found 327.0893.

Methyl 2-(2-methoxyphenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3ac). Pure white solid (116 mg, 72%) mp: 129-131 °C, eluent (hexane/EtOAc = 7:1), ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 7.6 Hz, 1H), 7.27 (s, 1H), 7.23 – 7.15 (m, 2H), 7.03 – 6.97 (m, 2H), 6.84 (t, *J* = 7.6 Hz, 1H), 6.54 (d, *J* = 8.4 Hz, 1H), 3.84 (s, 3H), 3.28 (s, 3H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 156.8, 145.1, 137.2, 136.0, 132.1, 130.8, 128.5, 128.5, 128.3, 126.9, 120.1, 119.4, 110.1, 54.5, 51.2, 11.0. HRMS (ESI): *m/z* calcd for C₁₉H₁₈N₂O₃ [M + H]⁺ 323.1390 found 323.1395

Methyl 2-(3-bromophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3ad). Pure white solid (143 mg, 77%) mp: 137-140 °C, eluent (hexane/EtOAc = 7:1), ¹H NMR (400 MHz, CDCl₃) δ 7.66 (t, *J* = 1.8 Hz, 1H), 7.56 – 7.50 (m, 3H), 7.38 (d, *J* = 7.2 Hz, 1H), 7.22 – 7.13 (m, 3H), 7.03 (t, *J* = 7.8 Hz, 1H), 3.97 (s, 3H), 2.43 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 145.1, 138.8, 136.0, 131.7, 131.7, 131.5, 130.0, 129.7, 129.5, 129.0, 127.8, 126.9, 122.3, 51.8, 11.0. HRMS (ESI): *m/z* calcd for C₁₈H₁₅BrN₂O₂ [M + H]⁺ 371.0390 found 371.0393

Methyl 5-methyl-1-phenyl-2-(*m*-tolyl)-1H-imidazole-4-carboxylate (3ae). Yellow viscous solid (106 mg, 70%), eluent (hexane/EtOAc = 7:1), ¹H NMR (400 MHz, CDCl₃) δ 7.49 (q, *J* = 3.4 Hz, 3H), 7.40 (s, 1H), 7.19 (p, *J* = 4.0, 3.2 Hz, 2H), 7.09 – 7.01 (m, 2H), 6.95 (d, *J* = 7.4 Hz, 1H), 3.97 (s, 3H), 2.43 (s, 3H), 2.25 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 147.0, 138.4, 137.9,

136.4, 129.8, 129.7, 129.5, 129.4, 129.3, 128.6, 127.9, 127.7, 125.4, 51.7, 21.3, 11.1. **HRMS** (ESI): m/z calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441 found 307.1445

Methyl 2-(4-chlorophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3af). Yellow solid (124 mg, 76%) mp:133-135 °C, eluent (hexane/EtOAc = 7:1), **¹H NMR** (400 MHz, CDCl₃) δ 7.53 – 7.48 (m, 2H), 7.30 (s, 1H), 7.20 – 7.15 (m, 4H), 3.95 (s, 3H), 2.41 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.2, 145.6, 138.6, 136.0, 134.7, 129.9, 129.8, 129.5, 128.8, 128.3, 128.0, 127.7, 51.6, 10.9. **HRMS** (ESI): m/z calcd for C₁₈H₁₅ClN₂O₂ [M + H]⁺ 327.0895 found 327.0893

Methyl 2-(4-methoxyphenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3ag). Yellow solid (114 mg, 71%) mp:128-130 °C, eluent (hexane/EtOAc = 7:1), **¹H NMR** (400 MHz, CDCl₃) δ 7.52 – 7.46 (m, 3H), 7.32 – 7.29 (m, 1H), 7.28 (s, 1H) 7.19 (ddq, *J* = 5.8, 3.0, 1.4 Hz, 2H), 6.75 – 6.70 (m, 2H), 3.96 (s, 3H), 3.76 (s, 3H), 2.41 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.4, 159.7, 146.7, 138.1, 136.4, 130.0, 129.8, 129.2, 128.4, 127.8, 122.1, 113.4, 55.2, 55.1, 51.5, 11.0. **HRMS** (ESI): m/z calcd for C₁₉H₁₈N₂O₃ [M + H]⁺ 323.1390 found 323.1393

Methyl 2-(2,3-dichlorophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3ah). Yellow solid (132 mg, 73%) mp:136-138 °C, eluent (hexane/EtOAc = 7:1), **¹H NMR** (400 MHz, CDCl₃) δ 7.42 (dd, *J* = 8.2, 1.4 Hz, 1H), 7.39 – 7.37 (m, 3H), 7.31 – 7.28 (m, 1H), 7.17 – 7.12 (m, 3H), 3.94 (s, 3H), 2.47 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.1, 143.9, 137.5, 134.8, 133.1, 131.9, 131.5, 130.9, 129.3, 129.2, 128.7, 127.3, 127.3, 126.8, 51.6, 10.9. **HRMS** (ESI): m/z calcd for C₁₈H₁₄Cl₂N₂O₂ [M + H]⁺ 361.0505 found 361.0508

Methyl 2-(furan-2-yl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate (3ai). Pure white solid (104 mg, 74%) mp:127-129 °C, eluent (hexane/EtOAc = 7:1), **¹H NMR** (400 MHz, CDCl₃) δ 7.58 (d, *J* = 6.8 Hz, 3H), 7.28 (dd, *J* = 7.2, 1.6 Hz, 3H), 6.26 (dt, *J* = 3.2, 1.4 Hz, 1H), 5.92 (d, *J* = 3.4 Hz, 3H), 3.95 (s, 1H), 2.37 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.1, 143.9, 143.0, 139.0, 138.1, 135.6, 129.9, 129.9, 128.6, 127.8, 110.9, 109.8, 51.5, 10.5. **HRMS** (ESI): m/z calcd for C₁₆H₁₄N₂O₃ [M + H]⁺ 283.1077 found 283.1072

Methyl 5-methyl-1-phenyl-2-(thiophen-2-yl)-1H-imidazole-4-carboxylate (3aj). Yellow solid (103 mg, 69%) mp:125-128 °C, eluent (hexane/EtOAc = 7:1), **¹H NMR** (400 MHz, CDCl₃) δ 7.64 – 7.54 (m, 3H), 7.30 (dd, *J* = 4.8, 3.4 Hz, 2H), 7.20 (dt, *J* = 5.0, 1.4 Hz, 1H), 6.82 (ddd, *J* = 5.2, 3.6, 1.4 Hz, 1H), 6.73 (dd, *J* = 3.6, 2.0 Hz, 1H), 3.95 (s, 3H), 2.36 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.2, 142.1, 138.5, 135.7, 132.0, 130.2, 130.1, 128.6, 128.3, 128.3, 127.1, 126.8, 51.7, 10.8. **HRMS** (ESI): m/z calcd for C₁₆H₁₄N₂O₂S [M + H]⁺ 299.0849 found 299.0850

Methyl 1-(4-chlorophenyl)-5-methyl-2-phenyl-1H-imidazole-4-carboxylate (3ba). Pure white solid (123 mg, 76%) mp:132-135 °C, **¹H NMR** (400 MHz, CDCl₃) δ 7.49 – 7.45 (m, 2H), 7.38 – 7.34 (m, 2H), 7.28 – 7.21 (m, 3H), 7.16 – 7.12 (m, 2H), 3.96 (s, 3H), 2.43 (s, 3H). **¹³C NMR** (100 MHz, CDCl₃) δ 164.2, 146.7, 138.1, 135.4, 134.7, 130.1, 129.2, 129.1, 128.9, 128.8, 128.7, 128.1, 51.6, 11.0. **HRMS** (ESI): m/z calcd for C₁₈H₁₅ClN₂O₂ [M + H]⁺ 327.0895 found 327.0893

Methyl 5-methyl-2-phenyl-1-(p-tolyl)-1H-imidazole-4-carboxylate (3ca). Pure white solid (111 mg, 73%) mp:136-141 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.38 (dt, *J* = 6.8, 1.6 Hz, 2H), 7.27 – 7.17 (m, 5H), 7.07 – 7.04 (m, 2H), 3.95 (s, 3H), 2.43 (s, 3H), 2.41 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 146.8, 139.4, 138.6, 133.6, 130.4, 129.6, 128.6, 128.5, 128.5, 128.0, 127.5, 51.6, 21.2, 11.0. **HRMS** (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441 found 307.1444

Methyl 5-methyl-2-phenyl-1-(m-tolyl)-1H-imidazole-4-carboxylate (3da). Yellow solid (109 mg, 71%) mp:138-141 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.30 (m, 4H), 7.27 – 7.18 (m, 3H), 6.99 (d, *J* = 10.2 Hz, 2H), 3.96 (d, *J* = 1.4 Hz, 3H), 2.42 (s, 3H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 146.7, 140.1, 138.6, 136.3, 130.2, 129.7, 129.6, 128.6, 128.6, 128.6, 128.2, 128.0, 124.9, 51.6, 21.3, 11.1. **HRMS** (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441 found 307.1445

methyl 5-methyl-2-phenyl-1-(o-tolyl)-1H-imidazole-4-carboxylate (3ea). Yellow viscous solid (99 mg, 65%), ¹H NMR (400 MHz, CDCl₃) δ 7.33 (d, *J* = 7.6 Hz, 4H), 7.22 (s, 1H), 7.13 (p, *J* = 7.4 Hz, 4H), 3.89 (s, 3H), 2.25 (s, 3H), 1.82 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 146.3, 138.1, 135.6, 135.3, 131.4, 129.8, 129.6, 128.6, 128.6, 128.2, 128.0, 127.8, 127.3, 51.5, 17.2, 10.5. **HRMS** (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441 found 307.1446

Methyl 5-methyl-1-(naphthalen-1-yl)-2-phenyl-1H-imidazole-4-carboxylate (3fa). Pure white solid (138 mg, 81%) mp:140-143 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, *J* = 14.2, 8.2 Hz, 2H), 7.55 (dt, *J* = 18.6, 7.8 Hz, 4H), 7.35 (d, *J* = 6.8 Hz, 2H), 7.29 (d, *J* = 5.8 Hz, 1H), 7.14 (t, *J* = 7.4 Hz, 1H), 7.06 (t, *J* = 7.6 Hz, 2H), 4.00 (s, 3H), 2.27 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 147.5, 139.4, 134.0, 132.6, 130.1, 130.1, 129.4, 128.7, 128.6, 128.5, 128.1, 127.9, 127.9, 127.1, 126.3, 125.3, 121.9, 51.6, 10.5. **HRMS** (ESI): *m/z* calcd for C₂₂H₁₈N₂O₂ [M + H]⁺ 343.1441 found 343.1447.

Methyl 1-butyl-5-methyl-2-phenyl-1H-imidazole-4-carboxylate (3ga). Pure white solid (78 mg, 57%) mp:122-125 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.61 – 7.41 (m, 5H), 3.92 (t, *J* = 7.0 Hz, 5H), 2.64 (s, 3H), 1.65 – 1.55 (m, 2H), 1.30 – 1.17 (m, 2H), 0.84 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 147.5, 136.8, 130.5, 129.3, 129.2, 128.5, 128.3, 51.5, 44.3, 32.4, 19.7, 13.5, 10.4. **HRMS** (ESI): *m/z* calcd for C₁₆H₂₀N₂O₂ [M + H]⁺ 273.1598 found 273.1595.

Methyl 1-cyclohexyl-5-methyl-2-phenyl-1H-imidazole-4-carboxylate (3ha). Yellow solid (80 mg, 54%) mp:140-143 °C, eluent (hexane/EtOAc = 7:1), ¹H NMR (400 MHz, CDCl₃) δ 7.51 – 7.43 (m, 5H), 4.11 (ddt, *J* = 10.4, 7.0, 3.4 Hz, 1H), 3.90 (s, 3H), 2.79 (s, 3H), 1.96 – 1.83 (m, 6H), 1.69 (d, *J* = 12.2 Hz, 1H), 1.29 – 1.12 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 147.9, 136.4, 131.3, 129.8, 129.3, 128.8, 128.3, 57.9, 51.4, 32.0, 26.1, 25.1, 12.0. **HRMS** (ESI): *m/z* calcd for C₁₈H₂₂N₂O₂ [M + H]⁺ 299.1754, found 299.1757.

Methyl 1-benzyl-5-methyl-2-phenyl-1H-imidazole-4-carboxylate (3ia). white solid (93 mg, 61%) mp:130-133 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.49 (m, 2H), 7.41 – 7.32 (m, 6H), 7.00 – 6.96 (m, 2H), 5.21 (s, 2H), 3.94 (s, 3H), 2.48 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 148.1, 137.4, 135.9, 129.8, 129.4, 129.2, 129.1, 128.8, 128.6, 127.9, 125.5, 51.6, 48.1, 10.5. **HRMS** (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441, found 307.1443.

Ethyl 5-methyl-1,2-diphenyl-1H-imidazole-4-carboxylate (3ja). Pure white solid (118 mg, 77%) mp:123-125 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.49 (dq, *J* = 5.4, 1.8 Hz, 3H), 7.40 – 7.35 (m, 2H), 7.27 – 7.17 (m, 5H), 4.46 (dt, *J* = 7.2, 1.6 Hz, 2H), 2.43 (s, 3H), 1.45 (t, *J* = 8.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.1, 146.8, 138.2, 136.4, 129.8, 129.7, 129.3, 129.0, 128.8, 128.6, 128.0, 127.9, 60.5, 14.6, 11.2. HRMS (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441, found 307.1445.

Tert-Butyl 5-methyl-1,2-diphenyl-1H-imidazole-4-carboxylate (3ka). Pure white solid (125 mg, 75%) mp:141-144 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.52 – 7.47 (m, 1H), 7.39 (d, *J* = 7.4 Hz, 1H), 7.25 – 7.15 (m, 2H), 2.38 (s, 1H), 1.66 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.2, 146.4, 137.0, 136.5, 130.2, 129.7, 129.7, 129.2, 128.6, 128.5, 128.0, 127.9, 80.9, 28.4, 11.3. HRMS (ESI): *m/z* calcd for C₂₁H₂₂N₂O₂ [M + H]⁺ 335.1754, found 335.1756.

Ethyl 1,2,5-triphenyl-1H-imidazole-4-carboxylate (3la). Pure white solid (68 mg, 37%) mp:133-137 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.43 – 7.40 (m, 2H), 7.35 – 7.28 (m, 4H), 7.27 – 7.20 (m, 7H), 7.00 (dt, *J* = 6.6, 1.6 Hz, 2H), 4.33 (q, *J* = 7.2 Hz, 2H), 1.27 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.1, 147.4, 140.1, 136.2, 130.8, 129.9, 129.5, 129.1, 128.9, 128.8, 128.6, 128.5, 128.1, 128.0, 127.8, 127.6, 60.4, 14.2. HRMS (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 369.1598, found 369.1596.

Methyl 5-ethyl-1,2-diphenyl-1H-imidazole-4-carboxylate (3ma). Pure white solid (110 mg, 72%) mp:136-138 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.48 (tq, *J* = 4.2, 2.2, 1.6 Hz, 3H), 7.36 – 7.33 (m, 2H), 7.23 – 7.15 (m, 5H), 3.96 (s, 3H), 2.85 (q, 2H), 1.06 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.2, 146.8, 144.3, 136.3, 129.8, 129.6, 129.5, 128.8, 128.7, 128.7, 128.1, 128.0, 51.6, 17.9, 13.9. HRMS (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 307.1441, found 307.1444.

Methyl 5-isopropyl-1,2-diphenyl-1H-imidazole-4-carboxylate (3na). Pure white solid (117 mg, 73%) mp:143-147 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.50 (t, *J* = 6.4 Hz, 3H), 7.32 (dd, *J* = 13.4, 7.0 Hz, 3H), 7.22 (d, *J* = 6.6 Hz, 4H), 3.97 (s, 3H), 3.19 – 3.08 (m, 1H), 1.34 (d, *J* = 6.8 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 164.1, 147.5, 146.3, 136.6, 129.7, 129.6, 129.5, 128.8, 128.5, 128.4, 128.0, 127.9, 51.7, 25.4, 20.1. HRMS (ESI): *m/z* calcd for C₁₉H₁₈N₂O₂ [M + H]⁺ 321.1598, found 321.1595.



1-(5-methyl-1,2-diphenyl-1H-imidazol-4-yl)ethan-1-one (3oa) Yellow solid (88 mg, 64%) mp:127-133 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.50 (h, *J* = 2.8 Hz, 3H), 7.39 – 7.35 (m, 2H), 7.28 – 7.18 (m, 5H), 2.71 (s, 3H), 2.44 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 196.7, 145.8, 137.0, 136.7, 136.2, 129.9, 129.8, 129.3, 128.6, 128.5, 128.3, 127.8, 27.7, 11.3. HRMS (ESI): calcd for C₁₈H₁₆N₂O [M + H]⁺ 277.1335, found 277.1331.

Ethyl 2-(4-bromophenyl)-1-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate. Yellow solid (1.3 g, 58%). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 2.4 Hz, 1H), 7.42 – 7.37 (m, 3H), 7.27 – 7.23 (m, 2H), 7.20 (d, *J* = 8.6 Hz, 1H), 4.45 (q, *J* = 7.2 Hz, 2H), 2.36 (s, 3H), 1.44 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.7, 145.7, 138.3, 136.8, 133.8, 132.7, 131.6, 130.9, 130.7, 129.7, 129.7, 128.8, 128.3, 123.6, 60.7, 14.6, 10.6. HRMS (ESI): calcd for C₁₉H₁₅BrCl₂N₂O₂ [M + H]⁺ 452.9767, found 452.9764.



methyl 5-methyl-2-phenyloxazole-4-carboxylate (3a'a) $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.12 – 8.05 (m, 2H), 7.47 (dd, $J = 5.2, 1.8$ Hz, 3H), 3.96 (s, 3H), 2.72 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 162.9, 159.7, 156.5, 130.8, 128.8, 128.5, 126.6, 126.5, 52.1, 12.2.

8. NMR spectra of products:



Methyl 5-methyl-1,2-diphenyl-1H-imidazole-4-carboxylate(3aa)





Methyl 2-(2-chlorophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3ab)




Methyl 2-(2-methoxyphenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3ac)





Methyl 2-(3-bromophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3ad)




Methyl 5-methyl-1-phenyl-2-(m-tolyl)-1H-imidazole-4-carboxylate(3ae)




$^1\text{H NMR}$ (400 MHz, CDCl_3)





$^{13}\text{C NMR}$ (100 MHz, CDCl_3)




Methyl 2-(4-chlorophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3af)




¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




Methyl 2-(4-methoxyphenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3ag)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)





Methyl 2-(2,3-dichlorophenyl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3ah)




Methyl 2-(furan-2-yl)-5-methyl-1-phenyl-1H-imidazole-4-carboxylate(3ai)





Methyl 5-methyl-1-phenyl-2-(thiophen-2-yl)-1H-imidazole-4-carboxylate(3aj)




Methyl 1-(4-chlorophenyl)-5-methyl-2-phenyl-1H-imidazole-4-carboxylate(3ba)





^1H NMR (400 MHz, CDCl_3)





^{13}C NMR (100 MHz, CDCl_3)






Methyl 5-methyl-2-phenyl-1-(p-tolyl)-1H-imidazole-4-carboxylate(3ca)





Methyl 5-methyl-2-phenyl-1-(m-tolyl)-1H-imidazole-4-carboxylate(3da)




Methyl 5-methyl-2-phenyl-1-(o-tolyl)-1H-imidazole-4-carboxylate (3ea)





Methyl 5-methyl-1-(naphthalen-1-yl)-2-phenyl-1H-imidazole-4-carboxylate(3fa)




Methyl 1-butyl-5-methyl-2-phenyl-1H-imidazole-4-carboxylate(3ga)




¹H NMR (400 MHz, CDCl₃)




Methyl 1-cyclohexyl-5-methyl-2-phenyl-1H-imidazole-4-carboxylate(3ha)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)





Methyl 1-benzyl-5-methyl-2-phenyl-1H-imidazole-4-carboxylate(3ia)




Ethyl 5-methyl-1,2-diphenyl-1H-imidazole-4-carboxylate(3ja)





Tert-Butyl 5-methyl-1,2-diphenyl-1H-imidazole-4-carboxylate(3ka)




Ethyl 1,2,5-triphenyl-1H-imidazole-4-carboxylate(3la)




¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)




Methyl 5-ethyl-1,2-diphenyl-1H-imidazole-4-carboxylate(3ma)





¹H NMR (400 MHz, CDCl₃)





¹³C NMR (100 MHz, CDCl₃)





Methyl 5-isopropyl-1,2-diphenyl-1H-imidazole-4-carboxylate(3na)




1-(5-methyl-1,2-diphenyl-1H-imidazol-4-yl)ethan-1-one(30a)





Ethyl 2-(4-bromophenyl)-1-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate




Methyl 5-methyl-2-phenyloxazole-4-carboxylate (3a'a)



^1H NMR (400 MHz, CDCl_3)




^{13}C NMR (100 MHz, CDCl_3)




9. HRMS (ESI) of intermediates

Manuscript (Scheme 5 Control experiment)



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.8 Bar
Focus	Not active	Set Capillary	5500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	6.0 l/min
Scan End	1000 m/z	Set Collision Cell RF	150.0 Vpp	Set Divert Valve	Waste



Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.8 Bar
Focus	Not active	Set Capillary	5500 V	Set Dry Heater	200 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1000 m/z	Set Collision Cell RF	150.0 Vpp	Set Divert Valve	Waste

